| Line Item | 2025-12-31 | Y/Y |
|---|---|---|
| Revenue | $742.9M | -28.8% |
| Cost of Revenue | $326.2M | -52.1% |
| R&D Expense | $53.2M | -24.8% |
| SG&A Expense | $186.1M | -39.6% |
| Operating Income | $100.1M | +192.1% |
| Pre-tax Income | $82.8M | +157.9% |
| Income Tax | $30.2M | -36.7% |
| Net Income | $52.6M | +127.6% |
| EPS (Basic) | $0.98 |
| Line Item | 2025-12-31 | Y/Y |
|---|---|---|
| Cash & Equivalents | $205.4M | +106.4% |
| Accounts Receivable | $84.2M | -45.5% |
| Inventory | $343.4M | +10.2% |
| Current Assets | $662.5M | +10.7% |
| Total Assets | $1.32B | -5.1% |
| Current Liabilities | $132.2M | -18.6% |
| Long-term Debt | $589.7M | -15.8% |
| Line Item | 2025-12-31 | Y/Y |
|---|---|---|
| Operating Cash Flow | $170.6M | +190.6% |
| Capital Expenditures | $13.8M | -39.7% |
| Investing Cash Flow | $69.4M | -44.6% |
| Financing Cash Flow | -$136.6M | +28.1% |
| Free Cash Flow | $156.8M | +338.0% |
| +127.2% |
| EPS (Diluted) | $0.93 | +125.8% |
| Total Liabilities |
| $796.0M |
| -12.2% |
| Stockholders' Equity | $522.6M | +8.2% |